Aadi Bioscience, Inc. (Aadi), is a privately held biopharmaceutical company focused on development and commercialization of precision medicines targeted to rare mutation-driven diseases. Aadi’s initial focus is on the development of nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009) for diseases driven by mTOR pathway activation through mutations or deletions of specific genes such as TSC1, TSC2 or PTEN.
For its first indication, advanced malignant PEComa (perivascular epithelioid-cell tumor), the company has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and recently initiated submission of a rolling New Drug Application (NDA) to the FDA. Malignant PEComa is rare form of sarcoma driven often driven by mutations in the mTOR pathway for which there is currently no approved therapy.
Aadi plans to continue its precision medicine approach in tumor-agnostic indications for TSC1 and TSC2 mutated tumors, other cancers that have mutations in PTEN, and diseases outside of oncology that are driven by mTOR activation.
Please check out Our Science and Therapeutic Programs for information about our work.